Celgene - Articles and news items

NICE recommends Apremilast for treating psoriatic arthritis

Industry news / 11 October 2016 / Niamh Louise Marriott, Digital Content Producer

The committee felt the addition of apremilast to the existing treatments would give patients access to a treatment with a different mechanism of action…

EC approves Revlimid for mantle cell lymphoma

Industry news / 15 July 2016 / Victoria White, Digital Content Producer

Celgene’s Revlimid (lenalidomide) has been approved by the EC for the treatment of adult patients with relapsed or refractory mantle cell lymphoma…

Allergan files ANDA to the FDA for generic Abraxane

Industry news / 17 March 2016 / Victoria White

Allergan believes it is a first applicant to file an ANDA for generic Abraxane and, should it be approved, may get 180 days of generic market exclusivity…

Celgene’s Imnovid and Abraxane recommended for use in Ireland

Industry news / 29 February 2016 / Victoria White

Celgene has announced that that of the Health Service Executive (HSE) of Ireland has recommended two cancer treatments: Imnovid and Abraxane…

Celgene announces 72-week study results for ozanimod in MS

Industry news / 18 February 2016 / Victoria White

Reductions in brain lesions at week 24 were maintained while relapses were further reduced at week 72 with continuous ozanimod treatment…

New analyses of second-line treatment following AG in pancreatic cancer

Industry news / 25 January 2016 / Victoria White

Celgene has announced results from multiple analyses evaluating second-line treatments following Abraxane and gemcitabine (AG) in metastatic pancreatic cancer patients.

EC approves Vidaza as a new treatment for elderly patients with AML

Industry news / 30 October 2015 / Victoria White

Dr Hervé Dombret says the ‘announcement brings hope to patients with AML, particularly the elderly and more frail patients who cannot undergo intensive therapies’…

Celgene announces maintenance results for Ozanimod in ulcerative colitis

Industry news / 20 October 2015 / Victoria White

In the trial, a significantly greater proportion of patients on Ozanimod achieved or maintained clinical remission at 32 weeks compared with those on placebo…

CHMP adopts positive opinion of azacitidine for elderly patients with AML

Industry news / 25 September 2015 / Victoria White

The CHMP adopted a positive opinion for an expanded indication of azacitidine for the treatment of adult patients aged 65 years or older with acute myeloid leukaemia who are not eligible for haematopoietic stem cell transplantation…

NICE says ‘no’ to apremilast for psoriatic arthritis

Industry news / 3 September 2015 / Victoria White

NICE has published final draft guidance which does not recommend apremilast, saying that there is not enough evidence to demonstrate apremilast slows progression of psoriatic arthritis…

Celgene completes acquisition of Receptos for $7.2 billion

Industry news / 28 August 2015 / Victoria White

Celgene has completed its acquisition of Receptos, significantly enhancing Celgene’s Inflammation & Immunology pipeline with the addition of Ozanimod…

Celgene to acquire Receptos for $7.2 billion

Industry news / 15 July 2015 / Victoria White

Celgene and Receptos have signed a definitive agreement in which Celgene has agreed to acquire Receptos for approximately $7.2 billion…

  • Page 1 of 2
  • 1
  • 2
  • >


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...